KOSDAQElectronic Components361390

Genohco

₩13,840▲ 4.85%2026-10-02 close
Market Cap
₩135.6B
Turnover
₩700M
Volume
50,000 shares
Shares out.
9.7M
PER
—
PBR
1.6×
EPS
-₩99
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close

01

Report overview

Under KAI, Awaiting Major Space-Defense Orders

Since Korea Aerospace Industries (KAI) became its controlling shareholder in July 2025, Genocov has been positioned across satellite communications, avionics and defense components while awaiting a wave of large second-half project orders.

  1. 1

    KAI became the controlling shareholder (34.41% stake) through a share acquisition and new share issuance in July 2025, raising expectations of captive demand.

  2. 2

    As of the first quarter of 2026, segment mix was satellite communications 20.7%, avionics 13.4%, EGSE/inspection equipment 31.6% and defense components 34.4%, with the latter two exceeding half of revenue.

  3. 3

    Operating profit briefly turned positive in the third quarter of 2025 but reverted to losses in the fourth quarter of 2025 and the first quarter of 2026, while second-quarter 2026 revenue contracted further.

  4. 4

    Large-scale orders are slated for the second half, including the roughly KRW 3.3 trillion ANASIS-III program, the roughly KRW 1.4 trillion small SAR satellite project and the multipurpose satellite No.8 program, making backlog expansion a key watch item.

  5. 5

    The company cooperates with overseas prime contractors such as Viasat, Northrop Grumman and Airbus D&S, but most of these remain at the memorandum-of-understanding stage without confirmed earnings contribution.

02

Business structure

Genocov is a component supplier within Korea's aerospace and defense value chain, providing satellite communications equipment, avionics, EGSE/test equipment and core defense components.

As of the first quarter of 2026, segment revenue mix consisted of satellite communications 20.7%, avionics 13.4%, EGSE/inspection equipment 31.6% and defense components 34.4%.

The satellite communications segment covers satellite payloads, satellite bodies and ground stations, with its X-Band Transmitter having flight heritage on the Next-Generation Medium Satellites 1 through 3.

The avionics segment, built on its KAI relationship, supplies interference-blocking units for the T/FA-50 family and the KF-21 fighter.

The EGSE/test-equipment segment is considered a cash-cow business, since developers of satellite payload equipment must build EGSE regardless, allowing it to benefit alongside rising payload supply.

The defense core-component segment develops and produces cables and communications equipment suited to military operating environments, delivering high revenue visibility once mass production follows development completion.

Key customers include KAI, Hanwha Systems and LIG Nex1, from whom the company has secured a stable order base by earning recognition for quality and technical capability.

After KAI became the controlling shareholder in July 2025 through a share acquisition and new share issuance (34.41% stake), Genocov gained access to captive volume from KAI in satellite payloads, small satellite bodies and core avionics components.

Overseas, the company holds cooperation with Viasat on satellite communications/MRO, with Northrop Grumman on a Korean minesweeper helicopter program, and prior project history with Airbus D&S on military satellite ground operations, though most of these remain at the memorandum-of-understanding stage.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q2₩14B-₩1.4B−10.0%
2025Q3₩17.9B₩400M2.1%
2025Q4₩17.2B-₩200M−1.1%
2026Q1₩11.6B-₩1.2B−10.6%
2026Q2₩10.9B-₩700M−6.4%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩50.7B₩3.2B₩2.7B6.2%8.0%87.3%
2023₩55.1B₩1.2B₩1.7B2.1%4.7%90.2%
2024₩56.8B-₩2.2B-₩3.1B−3.8%−9.0%154.4%
2025₩59.6B-₩2.1B-₩2.1B−3.5%−4.1%69.3%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-23

04

Earnings analysis

Genocov's annual revenue rose steadily from KRW 50.7 billion in 2022 to KRW 55.1 billion in 2023, KRW 56.8 billion in 2024 and KRW 59.6 billion in 2025.

Profitability, however, fluctuated: operating margin fell from 6.2% (operating profit of KRW 3.2 billion) in 2022 to 2.1% (KRW 1.2 billion) in 2023, then turned negative at -3.8% (operating loss of KRW 2.2 billion) in 2024 and -3.5% (KRW 2.1 billion loss) in 2025, marking two consecutive years of operating losses.

Net income followed the same pattern, moving from profits of KRW 2.7 billion in 2022 and KRW 1.7 billion in 2023 to losses of KRW 3.1 billion in 2024 and KRW 2.1 billion in 2025.

On a quarterly basis, the third quarter of 2025 briefly turned profitable with revenue of KRW 17.9 billion and operating profit of KRW 0.38 billion, but the fourth quarter reverted to a loss with revenue of KRW 17.2 billion and an operating loss of KRW 0.19 billion.

The first quarter of 2026 saw losses widen to an operating loss of KRW 1.23 billion and a net loss of KRW 0.82 billion on revenue of KRW 11.6 billion, while the second quarter of 2026 saw revenue shrink further to KRW 10.9 billion with an operating loss of KRW 0.70 billion, though net income turned slightly positive at KRW 0.19 billion.

On the balance sheet, equity jumped to KRW 51.8 billion in 2025 from KRW 34.3 billion in 2024, and the debt ratio fell from 154.4% to 69.3%, changes attributable to the new share issuance tied to KAI's July 2025 entry as controlling shareholder.

Cash flow, however, deteriorated, with operating cash flow at negative KRW 19.8 billion in 2025 versus positive KRW 12.2 billion in 2024, reflecting the company's development-heavy business mix in which quarterly profitability swings with project stage and cost structure.

05

Industry analysis

Korea's space and defense industry sits in a cycle driven by the launch of the Korea AeroSpace Administration and stronger national-security space policy, with a series of government-led projects moving forward.

Multiple national space programs, including the Korea Positioning System (KPS), the low-earth-orbit K-LEO communications satellite program and reconnaissance satellite deployment, are being ordered sequentially alongside budget allocations.

In defense, the start of mass production for the KF-21 Boramae and expanding exports of systems such as Cheongung are expected to generate downstream benefits for component suppliers.

Genocov has built cooperative relationships with domestic prime contractors including KAI, Hanwha Systems and the Korea Aerospace Research Institute (KARI), drawing on its localization track record for satellite core components such as the X-Band Transmitter and S-Band Transponder as well as its localized interference-blocking units.

Few domestic companies span satellite payloads, avionics and defense core components simultaneously, making Genocov's diversified portfolio a relative point of differentiation in the competitive landscape.

That said, the industry's reliance on government budget execution timing and system-development schedules means revenue recognition is inherently exposed to ordering delays or program restructuring.

More recently, Hanwha Aerospace's equity investment in KAI signals strengthening cooperation among larger domestic groups within the space and aerospace sector.

06

Outlook

Combining company disclosures with brokerage estimates, second-half order momentum stands as the key variable for the earnings outlook. Large pending orders include the roughly KRW 3.3 trillion ANASIS-III program, the roughly KRW 1.4 trillion small SAR satellite project and the multipurpose satellite No.8 program.

KB Securities estimated that if Genocov also wins the multipurpose satellite No.8 contract, year-end 2026 order backlog could expand to around KRW 150 billion, presenting this as a factor raising visibility for a second-half earnings turnaround.

Earlier, in a September 2025 report, Hana Securities had projected year-end backlog of around KRW 120 billion.

Yuanta Securities, in a May 2026 report, projected 2026 revenue of KRW 85 billion and expected an operating-profit turnaround, noting the company secured roughly KRW 14.5 billion in orders in the first quarter of 2026 including onboard computer development for a low-earth-orbit communications satellite with KAI.

In February 2026, Genocov won a contract to develop the onboard computer (OBC) for the K-LEO program, often described as Korea's version of Starlink, with related EGSE revenue expected to be recognized progressively.

Production of the KF-21 interference-blocking unit is expected to expand the avionics segment's revenue over the long term under a planned production run of 120 units through 2032.

KB Securities cited this order pipeline alongside the potential for group-linked order synergies and customer diversification following KAI's entry as key checkpoints going forward.

07

Valuation

PER
—
PBR
1.6×
ROE
-1.8%
EPS
-₩99
BPS
₩7,473
Dividend per share
₩0

Genocov's share price currently trades at a certain premium relative to net asset value, which can be interpreted as reflecting both the 2025 improvement in capital structure (equity expansion from the new share issuance tied to KAI's entry) and market expectations for the space/defense order pipeline.

In the past, around 2022-2023 when the company was profitable, a valuation band relative to domestic peers had formed, and one brokerage assessed that the stock traded at a discounted multiple versus the domestic peer average based on 2024 earnings.

However, since that historical multiple was set during a period when the company remained profitable, it warrants caution when compared against the consecutive losses of 2024-2025 and continued losses in the first half of 2026.

Looking at the most recent four quarters (third quarter of 2025 through second quarter of 2026), only one quarter (third quarter of 2025) posted an operating profit while the other three recorded operating losses, indicating that profitability recovery has not yet been consistent on a quarterly basis.

With no recent dividend payments, the stock's appeal from a dividend-yield perspective is considered limited.

Ultimately, current valuation appears to reflect market expectations for the realization of large second-half orders and the timing of tangible KAI synergy materialization more than trailing earnings performance.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-23

08

Bull factors

Captive Demand from KAI

KAI's entry as controlling shareholder (34.41% stake) in July 2025 opened up captive volume from KAI in satellite payloads, small satellite bodies and core avionics components.

Hanwha Aerospace's equity investment in KAI is strengthening cooperation among large domestic groups in the space/aerospace sector, which is also cited as a potential benefit for Genocov. Its long-standing relationships with KAI and Hanwha Systems could form the basis for future order-linked synergies.

Large Order Pipeline

Large space/defense project orders are slated for the second half, including the roughly KRW 3.3 trillion ANASIS-III program, the roughly KRW 1.4 trillion small SAR satellite project and the multipurpose satellite No.8 program.

Genocov's heritage of supplying an S-Band Transponder for the Next-Generation Small Satellite No.1 and its experience with a SAR satellite power supply unit are cited as reasons it could benefit if it wins related contracts.

KB Securities estimated that successful wins in these programs could expand year-end 2026 backlog to KRW 150 billion.

Stable Cash-Cow Segments

The EGSE/test-equipment segment supplies equipment that satellite payload developers must build regardless, allowing it to benefit alongside rising payload supply.

The defense core-component segment also delivers relatively high revenue visibility, as it supplies the military based on mass-production volume once development is complete. Together, these two segments are seen as securing a stable portion of consolidated revenue.

09

Bear factors

Earnings Volatility and Consecutive Losses

Genocov posted consecutive operating and net losses in 2024 and 2025, and operating losses continued in both the first and second quarters of 2026.

The pattern of a single profitable quarter in the third quarter of 2025 followed by a return to losses in the fourth quarter and the first half of 2026 shows that profitability recovery has not yet stabilized.

A structural feature behind this is the company's development-heavy business mix, where quarterly profitability swings with project stage and cost structure.

Declining Revenue Scale

Quarterly revenue declined consecutively from a peak of KRW 17.9 billion in the third quarter of 2025 to KRW 17.2 billion in the fourth quarter, KRW 11.6 billion in the first quarter of 2026 and KRW 10.9 billion in the second quarter.

This is attributable to project-based revenue recognition being concentrated in certain quarters before easing afterward, but there is a risk that revenue recovery could be delayed if second-half large orders fail to materialize.

Overseas Revenue Shift Still at MOU Stage

Genocov has partnership agreements with overseas prime contractors such as Viasat, Northrop Grumman and Airbus D&S, but most remain at the memorandum-of-understanding stage, too early to discuss earnings contribution.

If these do not progress to definitive contracts and mass-production supply, the timing of the mid- to long-term shift toward an export-driven revenue structure could remain uncertain.

10

Risk factors

Dependence on Government/Defense Budgets

Given the business's high dependence on government/defense projects, changes in budget execution and system-development schedules can affect performance. If the ordering of large programs such as ANASIS-III or the small SAR satellite project is delayed, plans to expand order backlog could be delayed as well.

Development-Stage Profitability Swings

Because the business mix is development-heavy, profitability can vary depending on project stage and cost structure.

There have been past instances where one-off factors such as loss provisions or inventory valuation losses repeatedly affected results, and the possibility of similar factors recurring cannot be ruled out.

Uncertainty Over Group-Linked Synergies

While expanded cooperation in satellite/aerospace business is anticipated following KAI's entry, how much group-linked order synergy and customer diversification will actually materialize remains unconfirmed. Changes in shareholding structure or group strategy could also alter the direction of this cooperation.

11

What to watch next

  1. Mid-November 2026

    Third-quarter 2026 results are due to be disclosed, and it will be worth checking whether second-half order momentum translates into an actual recovery in revenue and profitability.

  2. Fourth quarter of 2026

    It will be important to confirm whether the roughly KRW 3.3 trillion ANASIS-III program and the roughly KRW 1.4 trillion small SAR satellite project proceed to ordering and contractor selection.

  3. End of 2026

    Year-end disclosures should be checked against brokerage-estimated backlog targets of roughly KRW 120 billion to KRW 150 billion to see whether they are actually achieved.

  4. Early 2027

    Preliminary full-year 2026 results should be checked to determine whether operating profit turns positive and the extent of revenue growth.

  5. First half of 2027

    Further confirmation will be needed on the ordering and participation outcome of the multipurpose satellite No.8 program, and on whether MOUs with overseas prime contractors convert into definitive contracts.

12

Overall view

Genocov gained expectations of captive demand in satellite payloads, avionics and defense components after KAI became its controlling shareholder, but it also carries consecutive losses in 2024-2025 and continued operating losses through the first half of 2026.

The quarterly volatility of a brief profitable quarter in the third quarter of 2025 followed by a return to losses shows that a profitability recovery has not yet reached a stable trajectory.

Large second-half orders slated for programs such as ANASIS-III, the small SAR satellite project and multipurpose satellite No.8 are seen as the key variables for backlog and earnings turnaround, with brokerages projecting year-end backlog in the range of roughly KRW 120 billion to KRW 150 billion.

The improvement in capital structure (lower debt ratio) following KAI's entry is positive for financial stability, but the deterioration in operating cash flow in 2025 is also worth monitoring.

Cooperation with overseas prime contractors remains at the memorandum-of-understanding stage, leaving the timing of a shift toward export-driven revenue uncertain.

Ultimately, the key things to watch going forward are whether the planned large programs actually proceed to order and contract award, and whether any resulting quarterly earnings improvement proves sustainable.

This report is prepared for informational purposes only and does not include a buy/sell recommendation or target price.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. rdata.kbsec.com
  2. hanaw.com
  3. comp.fnguide.com
  4. ssl.pstatic.net
  5. stockeasy.intellio.kr
  6. m.irgo.co.kr
  7. rdata.kbsec.com
  8. ket.kr
  9. file.alphasquare.co.kr
  10. alphasquare.co.kr
  11. markets.hankyung.com
  12. stock.pstatic.net
  13. bondweb.co.kr
  14. investing.com
  15. judal.co.kr
  16. judal.co.kr
  17. littlebproject.com
  18. littlebproject.com

Report written 2026-09-12 · Data as of 2026-09-11

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.